Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

Key Inclusion Criteria:

- Participants must be between greater than or equal to (>=) 16 and less than or equal
to (<=) 80 years of age; participants less than (<) 18 years of age must weigh >=40 kg
and must have body mass index >=16.5 kg/m^2.

- Participants must have active moderate to severe ileal, ileocolic, or colonic CD at
baseline as defined by CDAI, presence of ulcerations that are characteristic to CD as
determined by a colonoscopy and as defined by the SES-CD score and assessed by the
average worst daily abdominal pain and/or average daily stool frequency.

- Participants must have a documented diagnosis (endoscopic with histology) of CD for
>=3 months before screening.

- Participants must be willing and able to undergo a colonoscopy during screening after
all other inclusion criteria have been met.

- Participants must have had an inadequate response to, or lost response to, or had an
intolerance to at least 1 conventional treatment such as sulfasalazine or mesalamine
(5-aminosalicylic acid [5-ASA]), glucocorticoids, or immunosuppressants (azathioprine
[AZA], 6-mercaptopurine [6-MP] or methotrexate [MTX]) or anti-tumor necrosis factor
(anti-TNF). Participants who have had an inadequate response to sulfasalazine or
mesalamine should have also failed at least 1 other conventional treatment such as
glucocorticoids.

- Participants receiving treatment(s) for CD are eligible provided they have been, and
are anticipated to be, on a stable dose for the designated period of time.

- Participants are males or nonpregnant, nonlactating females who, if sexually active,
agree to comply with the contraceptive requirements of the protocol, or females of
nonchildbearing potential.

Key Exclusion Criteria:

- Participants with indeterminate colitis, microscopic colitis, non-steroidal
anti-inflammatory drug-induced colitis, ischemic colitis, infectious colitis, or
clinical/histologic findings suggestive of ulcerative colitis.

- Participants with colonic dysplasia or neoplasia.

- Participants with past medical history or presence of toxic megacolon.

- Participants with presence of enterovesical or enterovaginal fistulae.

- Participants with current symptomatic diverticulitis or diverticulosis.

- Participants with obstructive colonic stricture, past medical history of colonic
resection, a history of bowel surgery within 6 months before screening, or who are
likely to require surgery for CD during the treatment period.

- Participants with past medical history of multiple small bowel resections resulting in
clinically significant short bowel syndrome.

- Participants requiring total parenteral nutrition.

- Participants with past medical history of bowel surgery resulting in an existing or
current stoma.

- Participants have had prior treatment with SHP647 (formerly PF-00547659).

- Participants with active enteric infections, Clostridium difficile infection or
pseudomembranous colitis, evidence of active cytomegalovirus infection or Listeria
monocytogenes, known active invasive fungal infections such as histoplasmosis or
parasitic infections, clinically significant underlying disease that could predispose
the participants to infections, or a history of serious infection (requiring
parenteral antibiotic and/or hospitalization) within 4 weeks before baseline.

- Participants with abnormal chest x-ray or other imaging findings at screening, such as
presence of active tuberculosis (TB), general infections, heart failure, or
malignancy.

- Participants with evidence of active or latent infection with Mycobacterium
tuberculosis (TB) or participants with this history who have not completed a generally
accepted full course of treatment before baseline are excluded. All other participants
must have either the Mantoux (purified protein derivative [PPD]) tuberculin skin test
or interferon-gamma release assay (IGRA) performed.

- Participants with a pre-existing demyelinating disorder such as multiple sclerosis or
new onset seizures, unexplained sensory motor, or cognitive behavioral, neurological
deficits, or significant abnormalities noted during screening.

- Participants with any unexplained symptoms suggestive of progressive multifocal
leukoencephalopathy (PML) based on the targeted neurological assessment during the
screening period.

- Participants with a significant concurrent medical condition at the time of screening
or baseline, including, but not limited to, the following:

1. Any major illness/condition or evidence of an unstable clinical condition (eg,
renal, hepatic, hematologic, GI [except disease under study], endocrine,
cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active
infection/infectious illness) that, in the investigator's judgment will
substantially increase the risk to the participant if he or she participates in
the study.

2. Cancer or history of cancer or lymphoproliferative disease within the previous 5
years (other than resected cutaneous basal cell carcinoma, squamous cell
carcinoma, or carcinoma in situ of the uterine cervix that has been treated with
no evidence of recurrence).

3. Presence of acute coronary syndrome (eg, acute myocardial infarction, unstable
angina pectoris) within 24 weeks before screening.

4. History of significant cerebrovascular disease within 24 weeks before screening.

- Participants who have had significant trauma or major surgery within 4 weeks before
screening, or with any major elective surgery scheduled to occur during the study.

- Participants with evidence of cirrhosis with or without decompensation (ie, esophageal
varices, hepatic encephalopathy, portal hypertension, ascites).

- Participants with primary sclerosing cholangitis.

- Participants with evidence of positive hepatitis B surface antigen (HBsAg) or
hepatitis B core antibody (HBcAb).

- Participants with chronic hepatitis C (HCV) (positive HCVAb and hepatitis C
ribonucleic acid [HCVRNA]).

Note: Participants who are HCVAb positive without evidence of HCVRNA may be considered
eligible (spontaneous viral clearance or previously treated and cured [defined as no
evidence of HCVRNA at least 12 weeks prior to baseline]).

- Participants with any of the following abnormalities in hematology and/or serum
chemistry profiles during screening.

1. Alanine aminotransferase and aspartate aminotransferase levels >= 3 x the upper
limit of normal (ULN)

2. Total bilirubin level >=1.5 × ULN or >2.0 × ULN if the participant has a known
documented history of Gilbert's syndrome.

3. Hemoglobin level <=80 grams per liter (g/L) (8.0 gram per deciliter [g/dL])

4. Platelet count <=100 × 10^9 per liter (/L) (100,000 cells per cubic millimeter
[cells/mm^3]) or >=1000 × 10^9/L (1,000,000 cells/mm^3)

5. White blood cell count <=3.5 × 10^9/L (3500 cells/mm^3)

6. Absolute neutrophil count <2 × 10^9/L (2000 cells/mm3)

7. Serum creatinine level >1.5 x ULN or estimated glomerular filtration rate <30
milliliter per minute per 1.73 square meter (mL/min/1.73m^2) based on the
abbreviated Modification of Diet in Renal Disease Study Equation.

Note: If platelet count is <150,000 cells/mm^3, a further evaluation should be
performed to rule out cirrhosis, unless another etiology has already been
identified.

- Participants with known human immunodeficiency virus (HIV) infection based on
documented history with positive serological test or positive HIV serologic test at
screening, tested at the site's local laboratory in accordance with country
requirements, or tested at the central laboratory.

Note: A documented negative HIV test within 6 months of screening is acceptable and does
not need to be repeated.

- Participants who have, or who have a history of (within 2 years before screening),
serious psychiatric disease, alcohol dependency, or substance/drug abuse of any kind
including abuse of medicinal marijuana (cannabis).

- Participants with any other severe acute or chronic medical or psychiatric condition
or laboratory or electrocardiogram (ECG) abnormality that may increase the risk
associated with study participation or investigational product administration or may
interfere with the interpretation of study results and, in the judgment of the
investigator, would make the participant inappropriate for entry into this study.

- Female participants who are planning to become pregnant during the study period.

- Participants who do not agree to postpone donation of any organ or tissue, including
male participants who are planning to bank or donate sperm and female participants who
are planning to harvest or donate eggs, for the duration of the study and through 16
weeks after last dose of investigational product.

NOTE: The above Inclusion/Exclusion criteria are NOT exhaustive and other Inclusion/
Exclusion criteria as defined in the protocol may apply.